Terms: = Lung cancer AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1
413 results:
1. Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell lung cancer Patients: A Field Synopsis and Meta-Analysis.
Sito H; Sharzehan MAK; Islam MA; Tan SC
Br J Biomed Sci; 2024; 81():11835. PubMed ID: 38450253
[No Abstract] [Full Text] [Related]
2. abcg2 transporter reduces protein aggregation in cigarette smoke condensate-exposed A549 lung cancer cells.
Ajenu EO; Seideneck AM; Pandellapalli E; Shinsky EM; Humphries CL; Aparicio NL; Sharma M; Marden JH; Krasilnikova MM
PLoS One; 2024; 19(3):e0297661. PubMed ID: 38442133
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.
Hanley MJ; Yeo KR; Tugnait M; Iwasaki S; Narasimhan N; Zhang P; Venkatakrishnan K; Gupta N
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):624-637. PubMed ID: 38288787
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells.
Mahgoub TM; Jordan EJ; Mahdi AF; Oettl V; Huefner S; O'Donovan N; Crown J; Collins DM
Cancer Chemother Pharmacol; 2024 May; 93(5):427-437. PubMed ID: 38226983
[TBL] [Abstract] [Full Text] [Related]
5. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Watanabe S; Furuya N; Nakamura A; Shiihara J; Nakachi I; Tanaka H; Nakao M; Minato K; Seike M; Sasaki S; Kisohara A; Takeuchi S; Honda R; Takamura K; Kagamu H; Yoshimura K; Kobayashi K; Kikuchi T
Eur J Cancer; 2024 Jan; 197():113469. PubMed ID: 38061214
[TBL] [Abstract] [Full Text] [Related]
6. I-CBP112 declines overexpression of ATP-binding cassette transporters and sensitized drug-resistant MDA-MB-231 and A549 cell lines to chemotherapy drugs.
Strachowska M; Gronkowska K; Sobczak M; Grodzicka M; Michlewska S; Kołacz K; Sarkar T; Korszun J; Ionov M; Robaszkiewicz A
Biomed Pharmacother; 2023 Dec; 168():115798. PubMed ID: 37913733
[TBL] [Abstract] [Full Text] [Related]
7. Activation of mTOR signaling in adult lung microvascular progenitor cells accelerates lung aging.
Mason EC; Menon S; Schneider BR; Gaskill CF; Dawson MM; Moore CM; Armstrong LC; Cho O; Richmond BW; Kropski JA; West JD; Geraghty P; Gomperts BN; Ess KC; Gally F; Majka SM
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37874650
[TBL] [Abstract] [Full Text] [Related]
8. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With
Park S; Kim TM; Han JY; Lee GW; Shim BY; Lee YG; Kim SW; Kim IH; Lee S; Kim YJ; Park JH; Park SG; Lee KH; Kang EJ; Kim JW; Shin SH; Ock CY; Nam BH; Lee J; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
J Clin Oncol; 2024 Apr; 42(11):1241-1251. PubMed ID: 37861993
[TBL] [Abstract] [Full Text] [Related]
9. Pharmacokinetics of the KRAS
Loos NHC; Retmana IA; Rijmers J; Wang Y; Gan C; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Biomed Pharmacother; 2023 Oct; 166():115304. PubMed ID: 37586117
[TBL] [Abstract] [Full Text] [Related]
10. Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysis.
Yokota H; Sato K; Sakamoto S; Okuda Y; Asano M; Takeda M; Nakayama K; Miura M
Cancer Chemother Pharmacol; 2023 Oct; 92(4):315-324. PubMed ID: 37500985
[TBL] [Abstract] [Full Text] [Related]
11.
Sałagacka-Kubiak A; Zawada D; Saed L; Kordek R; Jeleń A; Balcerczak E
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445716
[TBL] [Abstract] [Full Text] [Related]
12. Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
Yang Y; Zheng Q; Wang X; Zhao S; Huang W; Jia L; Ma C; Liu S; Zhang Y; Xin Q; Sun Y; Zheng S
Invest New Drugs; 2023 Apr; 41(2):254-266. PubMed ID: 37036582
[TBL] [Abstract] [Full Text] [Related]
13. Association of
Tanda M; Yamamoto K; Hori T; Nishiguchi H; Yagi M; Shimizu M; Konishi T; Ozaki T; Yoshioka N; Tachihara M; Ito T; Ikushima S; Omura T; Yano I
Anticancer Res; 2023 Apr; 43(4):1775-1783. PubMed ID: 36974789
[TBL] [Abstract] [Full Text] [Related]
14. Increased expression of the pathological O-glycosylated form of oncofetal fibronectin in the multidrug resistance phenotype of cancer cells.
Reis JSD; Santos MARDC; da Costa KM; Freire-de-Lima CG; Morrot A; Previato JO; Previato LM; da Fonseca LM; Freire-de-Lima L
Matrix Biol; 2023 Apr; 118():47-68. PubMed ID: 36882122
[TBL] [Abstract] [Full Text] [Related]
15. Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
Hata T; Sakaguchi C; Hirano K; Kobe H; Ishida M; Nakano T; Tachibana Y; Tamiya N; Shiotsu S; Takeda T; Yamada T; Yokoyama T; Tsuchiya M; Nagasaka Y
Thorac Cancer; 2023 Apr; 14(11):1004-1011. PubMed ID: 36866788
[TBL] [Abstract] [Full Text] [Related]
16. Cross-protective antibodies against common endemic respiratory viruses.
Cabán M; Rodarte JV; Bibby M; Gray MD; Taylor JJ; Pancera M; Boonyaratanakornkit J
Nat Commun; 2023 Feb; 14(1):798. PubMed ID: 36781872
[TBL] [Abstract] [Full Text] [Related]
17. [Correlation between the mRNA levels of bcrp and LUNX genes and pathological types and stages of patients with non-small cell lung cancer].
Chen D; Han W; Wang P; Ma H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Feb; 40(2):202-207. PubMed ID: 36709941
[TBL] [Abstract] [Full Text] [Related]
18. Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell lung cancer.
Ikeuchi N; Igata F; Kinoshita E; Kawabata T; Tan I; Osaki Y; Otsuka R; On R; Ikeda T; Nakao A; Sasaki T; Aoyama T; Hirano R; Harada T; Ebi N; Fujita M; Inoue H
Anticancer Res; 2023 Feb; 43(2):713-724. PubMed ID: 36697078
[TBL] [Abstract] [Full Text] [Related]
19. Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell lung cancer: a Prospective Observational Study.
Ishikawa E; Yokoyama Y; Chishima H; Kasai H; Kuniyoshi O; Kimura M; Hakamata J; Nakada H; Suehiro N; Nakaya N; Nakajima H; Ikemura S; Kawada I; Yasuda H; Terai H; Jibiki A; Kawazoe H; Soejima K; Muramatsu H; Suzuki S; Nakamura T
Invest New Drugs; 2023 Feb; 41(1):122-133. PubMed ID: 36637703
[TBL] [Abstract] [Full Text] [Related]
20. Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
Bruno R; Marchand M; Yoshida K; Chan P; Li H; Zou W; Mercier F; Chanu P; Wu B; Lee A; Li C; Jin JY; Maitland ML; Reck M; Socinski MA
Clin Cancer Res; 2023 Mar; 29(6):1047-1055. PubMed ID: 36595566
[TBL] [Abstract] [Full Text] [Related]
[Next]
